Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5411251 | 1.00 | MEN1 (0.53) | MEN1KMT2AHPGDATML3MBTL1 | |
| SCHEMBL5413378 | 1.00 | MEN1 (0.53) | MEN1KMT2AHPGDATML3MBTL1 | |
| SCHEMBL5010366 | 0.87 | CA2 (0.48) | SMN1; SMN2CXCR3LMNANAMPTPOLB | |
| SCHEMBL5005889 | 0.87 | LMNA (0.46) | HPGDGAASMN1; SMN2TSHRLMNA | |
| SCHEMBL5006331 | 0.82 | USP5 (0.41) | MEN1KMT2AHPGDL3MBTL1RECQL | |
| SCHEMBL1413483 | 0.81 | MEN1 (0.54) | MEN1KMT2AHPGDATML3MBTL1 | |
| SCHEMBL1413484 | 0.81 | MEN1 (0.54) | MEN1KMT2AHPGDATML3MBTL1 | |
| SCHEMBL4013129 | 0.80 | ALDH1A1 (0.48) | MEN1KMT2AL3MBTL1CYP2C9TSHR | |
| SCHEMBL4010049 | 0.80 | GAA (0.53) | MEN1KMT2AGAALMNANAMPT | |
| SCHEMBL1413808 | 0.80 | MEN1 (0.51) | MEN1KMT2AHPGDATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276516-B2 | CB1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088018-A1 | Cb1 antagonist compounds | CNR1, CNR2, CHRNA5 | MEN1 157/4885KMT2A 2691/4885HPGD 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.